[go: up one dir, main page]

WO2011132826A1 - Système d'administration transdermique de médicaments et composition pharmaceutique pour la prévention ou le traitement de maladies osseuses - Google Patents

Système d'administration transdermique de médicaments et composition pharmaceutique pour la prévention ou le traitement de maladies osseuses Download PDF

Info

Publication number
WO2011132826A1
WO2011132826A1 PCT/KR2010/005890 KR2010005890W WO2011132826A1 WO 2011132826 A1 WO2011132826 A1 WO 2011132826A1 KR 2010005890 W KR2010005890 W KR 2010005890W WO 2011132826 A1 WO2011132826 A1 WO 2011132826A1
Authority
WO
WIPO (PCT)
Prior art keywords
bisphosphonate
daim
amino
delivery system
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2010/005890
Other languages
English (en)
Inventor
Jong Sang Park
So Hee Nam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SNU R&DB Foundation
Original Assignee
SNU R&DB Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SNU R&DB Foundation filed Critical SNU R&DB Foundation
Publication of WO2011132826A1 publication Critical patent/WO2011132826A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders

Definitions

  • the present invention relates to a transdermal drug delivery system comprising (i) a bisphosphonate-based drug and (ii) a cationic amine compound linked to the bisphosphonate- based drug via an ionic bond, and a pharmaceutical composition comprising the drug delivery system for preventing or treating a bone disease.
  • Osteoporosis is a common disease characterized by low bone mass and structural deterioration of bone tissue, resulting in decreased bone strength and increased susceptibility to fractures.
  • the risk of fragility fractures increases in the hips and spines of postmenopausal women suffering from osteoporosis.
  • Hyperkyphosis which refers to an accentuated concave curvature and loss of vertebrata height, commonly affects patients with osteoporosis due to a weakened vertebrate.
  • the cause of osteoporosis is still undear, but low body weighty low calcium intake, sedentary life style and declining estrogen levels at menopause can result in increased bone turnover and a loss of bone mass.
  • Alendronate marketed under the brand name FOSAMAX, is one of the nitrogen- containing bisphosphonate agents that specifically inhibit bone resoption mediated by osteoclasis.
  • FOSAMAX is known to be poorly absorbed and cause adverse effects on the gastrointestinal tract.
  • Pamidronate disodium (AREDIA) is a commercially available drug for inhibiting bone resorption, usually administered as an intravenous infusion. Common side effects include pain, stiffening and irritation at the catheter insertion site, loss of appetite, vomiting, diantiea, dyspepsia, esophagitis and stomatitis.
  • Risedronate sodium (trade name ACTONEL) is water soluble but insoluble in organic solvents and has adverse effect on the upper gastrointestinal tract.
  • Ibandronate sodium (trade name BONIVA) is a white/grey colored powder soluble in water but insoluble in organic solvents. This drug has adverse side effects in the upper GI tract. It is recommended that no food be taken for 2 hours after taking etidronate sodium (trade name DIDRONEL) due to its adverse gastrointestinal side-effects.
  • Zbledronate (trade name ZOMETA) is the only bisphosphonate developed solely for use as an IV administration. However, fever, nausea, vomiting and higher incidents of upper GI disorders were reported in some patient groups.
  • transdermal delivery may be a desirable alternative to oral treatment.
  • a transdermal delivery system is beneficial when dealing with drugs that can cause adverse GI events or undergo liver metabolism, or for drugs that are poorly absorbed or easily disintegrated in GI. Transporting drugs across the skin layer is known to be an effective way to improve the bioavailability of the drug, and to reduce the potential GI adverse effects
  • bisphosphonates have low bioavailability and high upper GI adverse effects.
  • Currently developed bisphosphonate-based drugs are highly charged, and have trouble penetrating the lipid bilayer. These drugs also have high affinity to polycationic metal ions, such as calcium ions, that form a water insoluble complex that is difficult to be absorbed by the cell membrane of the GI tract [Int J Pharm 21:143-154(1984)].
  • the acidic pH of the small intestine pH 6-8) reduce the absorption of bisphosphonate drugs to less than
  • transdermal delivery system of bisphosphonate-based drugs Successful development of a transdermal delivery system of bisphosphonate-based drugs is expected to increase bioavailability and decreased the adverse side effects of the drug, therefore likely leading to increased patient compliance to the drug. Little information is available regarding transdermal delivery system of bisphosphonate throughout the world. This could be due to the low absorption rate of this drug in the patient body. Even oral administration of bisphosphonate shows less than 1% of bioavailability, therefore developing an appropriate penetration activator could successfully enhance the efficacy of this low level of bisphosphonate delivery.
  • Vertebral fracture is a common consequence of osteoporosis if left untreated. This can lead to chronic pain and decreased quality of life, which in turn could be a great burden on government health care. A therapeutic intervention that decreases fracture risk is essential for reducing the consequences of this debilitating condition.
  • the object of this invention is to develop a transdermal delivery system of risedronate and compare its efficacy with oral administration using animal models or healthy human subjects.
  • the ultimate goal of this invention is to apply our accumulated pharmacokinetic and clinical trial data into commercializing of a novel transdermal delivery system for bisphosphonate.
  • the present inventors have made intensive researches to enhance skin penetration and in vivo absorption rate of bisphosphonate-based drugs for prevention or treatment of bone diseases.
  • cationic amine compounds linked to bisphosphonate-based drugs via an ionic bond makes the bisphosphonate-based drug less hydrophilic and more hydrophobic, thereby dramatically increasing its skin penetration rate.
  • Figs, la and lb are graphs showing increased solubility of risedronate linked to diethylenetriamine (DETA) or L-arginine via ionic bonds in xylene or propylene carbonate.
  • DETA diethylenetriamine
  • Rg. 2a is a graph showing in vitro ⁇ penetration of risedronate linked to L-arginine via ionic bonds.
  • Rg. 2b is a graph showing in vitro skin penetration of risedronate linked to L-lysine via ionic bonds.
  • Rg. 3 is a graph showing in vitro skin penetration of risedronate linked to diethylenetriamine (DETA) via ionic bonds.
  • Rg.4 is an image showing results of the skin irritation test performed using risedronate with viscosity by Xanthan gum aqueous solution.
  • Rg.5 is an image showing representative results of the skin irritation test performed using risedronate and L-arginine (molar ratio 1:2) ionic compound with viscosity by Xanthan gum aqueous solution.
  • Rg.6 is an image showing representative results of the skin irritation test performed using risedronate and diethylenetriamine (DETA, molar ratio 1:1) ionic compound with viscosity by Xanthan gum aqueous solution.
  • DETA diethylenetriamine
  • Fig. 7a represents micro CT images of femur from ovariectomized mouse model treated with (a) Sham, (b) OVX-cti, (c) OVX-0.2% or (d) OVX-2%.
  • OVX-cti, OVX-0.2% and OVX-2% represent the drug delivery system of this invention containing 0 wt% risedronate, 0.2 wt% risedronate and 2 wt% risedronate linked to L-arginine, respectively.
  • Rg. 7b represents two-dimensional micro CT images of femur from ovariectomized mouse model treated with (a) Sham, (b) OVX-cti, (c) OVX-0.2% or (d) OVX-2%.
  • Rgs. 8a-8e represent BMC (Bone mineral contents), BMD (mg/cc; Bone Mineral Density), TMC (mg; Total Mineral Contents), TMD (mg/cc; Total Mineral Density) and BVF (Bone volume fraction) of ovariectomized mouse model treated with (A) OVX-cti, (B) OVX- 0.2% or (C) OVX-2%.
  • a transdermal drug delivery system comprising (i) a bisphosphonate-based drug and (ii) a cationic amine compound linked to the bisphosphonate-based drug via an ionic bond.
  • a method for delivering a drug via transdermal route which comprises administering to a subject a composition comprising (i) a bisphosphonate-based drug; and (ii) a cationic amine compound linked to the bisphosphonate-based drug via an ionic bond.
  • the present inventors have made intensive research to enhance skin penetration and in vivo absorption rate of bisphosphonate-based drugs for prevention or treatment of bone diseases.
  • cationic amine compounds linked to bisphosphonate-based drugs via an ionic bond makes the bisphosphonate-based drug less hydrophilic and more hydrophobic, thereby dramatically increasing its skin penetration rate.
  • bisphosphonate refers to a pyrophosphate analogue where the center oxygen atom in a P-O-P moiety is substituted with a carbon atom to from a P-C-P moiety. It should be noted that the term “bisphosphonate” as used herein in referring to the therapeutic agents of the present invention are meant to also encompass diphosphonates, biphosphonic acids, and diphosphonic acids, as well as salts and derivatives of these materials.
  • Ri is hydrogen, hydroxy or halo
  • R 2 is halo, CMO alkyl, CM 0 cydoalkyl, CMO heterocydoalkyl, C O heteroaryl, CMO aryi or CMO arylalkyl; the alkyl, cydoalkyl, aryl, arylalkyl, heterocydoalkyl and heteroaryl are substituted with halo, sulfur, amino, Ci -5 alkylamino or -s dialkylamino and contains 1-3 nitrogen atoms.
  • halo means halogen atoms, for instance induding fluoro, chloro, bromo, and iodo, preferably fluoro, chloro or bromo.
  • -Qo alkyl is defined herein to be a straight chain or branched chain saturated hydrocarbon groups containing 1-10 carbon atoms, induding methyl, ethyl, /7-propyl, isopropyl, isobutyl, /7-butyl, f-butyl, /7-hexyl, /Hxtyl and foctyl.
  • Cydoalkyl refers to cyclic hydrocarbon radicals containing 1- 10 carbon atoms, preferably “C 3 -Q cydoalkyl", induding cydopropyl, cydobutyl and cyclopentyl and cydooctyl. Cydoalkyl may be substituted with alkyl groups having 1-3 carbon atoms, preferably 1-methylcyclopropyl, 2-methylcydopentyl and 2-methylcydooctyl.
  • heterocydoalkyl refers to cydoalkyl in which one or more of the atoms forming the ring is a heteroatom selected, independently from N, 0, or S.
  • Non- exdus ' rve examples of heterocydoalkyl indude piperidyl, 4-morpholyl, 4-piperazinyl, pyrrolidinyl, peitiydropyrrolizinyl, 1,4-diazaper ydroepinyl, 1,3-dioxanyl, 1,4-dioxanyl and the like.
  • aryl means totally or partially unsaturated, substituted or unsubstituted monocylic or polycydic carbon rings, preferably phenyl, naphthyl, anthracene or pyrene. Meet preferably, the aryl group is substituted or unsubstituted phenyl, naphthyl or pyrene.
  • the monoaryl group e.g., phenyl may be substituted with various substituents, preferably halo, hydroxy, nitro, cyano, Q-Q alkyl and Q-Q alkoxy group. More preferably, nitro and Q-Q alkoxy groups.
  • alkoxy means -O alkyl groups, preferably methoxy. Where substituted with Q-Q substituted alkyl groups, halo, preferably chloro or fluoro substituted alkyl substituents may be used.
  • R 2 is biary, e.g. naphthyl, it may be substituted in various positions with various substituents, preferably halo, hydroxy, nitro, cyano, straight or branched, substituted or unsubstituted Q-Q alkyl, straight or branched Q-Q alkoxy, or substituted or unsubstituted amino groups, more preferably nitro or Q-Q alkoxy.
  • arylalkyl means aryl groups linked to a structure comprised of one or more alkyl groups, e.g. benzyl. More preferably, arylalkyl is alkylphenyl, alkylnaphthalene, alkyl anthracene, or alkylpyrene, most preferably, benzyl, methylnaphthalene or methylpyrene.
  • heteroaryl means heterocyclic aromatic groups containing heteroatoms such as N, O and S.
  • heteroaryl is heterobiaryl containing N atom as heteroatom.
  • alkylamino means alkyl groups having amino substituents.
  • dialkylamino refers to two alkyl groups having amino substituents.
  • the bisphosphonate-based drug is (4-amino-l- hydroxybutylidene)-bisphosphonate or 4-amine-l-hydroxybutane-l,l-bisphosphonic acid(alendronate); (dichloromethylene)-bisphosphonate (dodronate); (1-hydroxyethylidene)- bisphosphonate(etidronate); [l-hydroxy-3-(methylpentylamino) propylidene] bisphosphonate(evandronate); [(cydoheptylamino)-methylene] bisphosphonate (dmadronate, incadronate); [l-hydroxy-2-imidazo-(l,2-a) pyridine-3-ylethyledne] bisphosphonate (minodronate); (6-amino-l-hydroxyhexyleden) bisphosphonate (neridronate); [3- (dimethylamino)-hydroxy-propylidene] bisphosphonate (o
  • salts means salts of the bisphosphonate-based drug which are pharmaceutically acceptable, and which possess the desired pharmacological activity.
  • Such salts indude add addition salts formed with inorganic adds such as hydrochloric add, hydrobromic add, sulfuric add, nitric add, phosphoric add, and the like; or with organic adds such as acetic add, propionic add, hexanoic add, heptanoic add, cydopentanepropionic add, glycolic add, pyruvic add, lactic add, malonic add, sucdnic add, malic add, maleic add, flimaric add, tartatic add, citric add, benzoic add, o-( -hydroxybenzoyl)benzoic add, dnnamic add, mandelic add, methanesulfonic add, ethanesulfonic add, 1,2-ethanedisulfonic add, 2- hydroxyethanesul
  • Pharmaceutically acceptable salts also indude base addition salts which may be formed when addic protons present are capable of reacting with inorganic or organic bases.
  • Acceptable inorganic bases indude sodium hydroxide, sodium carbonate, potassium hydroxide, aluminum hydroxide and caldum hydroxide.
  • Acceptable organic bases indude ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine and the like.
  • the cationic amine compound used in the drug delivery system of this invention is selected from the group consisting of an amino add, diethylenetriamine (DETA), spermine, ethylene diamine, triethylene tetramine and tris(2- aminoethyl amine). More preferably, the cationic amine compound is the amino add.
  • amino add means compounds having both an amino group and carboxyl group.
  • the amino add indudes alanine, arginine, asparagine, aspartic add, citrulline, cysteine, cystine, selenocysteine, glutamine, glydne, histidine, isoleudne, leudne, lysine, methionine, ornithine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, hydroxy proline, y-carboxyglutamate, or Ophosphoserine.
  • Each amino acid has its typical isoelectric point (pi) where its mean charge becomes zero. For instance, certain amino adds have higher pi values than the physiological pH value (pH 7.4) and are positively charged under physiological pH conditions.
  • the cationic amine compound is used to form ionic bonds with oxygen anions from phophonate groups of bisphosphonate drugs, decreasing hydrophilic properties of bisphosphonate drugs.
  • the amino adds are used as cationic amine compounds, a suitable amino add can be selected depending on pH values of solutions for preparation of materials having ion bonds ⁇ i.e., drug delivery system of this invention).
  • the solution for preparing the drug delivery system has a pH value of 2
  • all amino adds described above with pi values of above 2 are positively charged.
  • the solution for preparing the drug delivery system has a pH 4-9.
  • the amino add as cationic amine compound is preferably Arg or Lys.
  • Non-limiting examples of solvents for forming ion bonds between the bisphosphonate- based drug and the cationic amine compound indude water, ethanol, 1,3-butylene glycol, glycerin, propylene glycol and combinations thereof.
  • the drug delivery system has the molar ratio of the bisphosphonate-based drug and the cationic amine compound of 1:0.01-50, more preferably 1:1-40, most preferably 1:2-30.
  • the molar ratio of 1:0.01-50 is advantageous for decreasing hydrophilic properties of bisphosphonate-based drugs by formation of ion bonds.
  • the molar ratio of the bisphosphonate-based drug to the cationic amine compound is preferably 1:0.01-10, more preferably 1:1-6, most preferably 1:1-4.
  • the molar ratio of the bisphosphonate-based drug to the cationic amine compound is preferably 1:0.01-10, more preferably 1:0.1-6, most preferably 1:0.5-5.
  • the bisphosphonate-based drug is contained in the amount of 0.01-20 wt% (more preferably 0.1-10 wt%, most preferably 1-5 wt%) based on the total weight of the drug delivery system.
  • the amount of 0.01-20 wt% for bisphosphonate-based drugs is desirable for the decrease in hydrophilic properties of bisphosphonate-based drugs by formation of ion bonds.
  • the drug delivery system of the present invention is developed for overcoming shortcomings associated with oral and intravenous administration of bisphosphonate-based drugs and suggests transdermal administration as alternatives.
  • the drug delivery system may be prepared in various forms such as solution, lotion, W/O emulsion, O/W emulsion, suspension, liposome, gel, hydrogel, cream, paste, patch or ointment
  • the drug delivery system may be prepared in the form of liposomes using phospholipids.
  • liposome encompasses any compartment enclosed by a lipid bilayer. Liposomes are also referred to as lipid vesides. In order to form a liposome the lipid molecules comprise elongated non-polar (hydrophobic) portions and polar (hydrophilic) portions. The hydrophobic and hydrophilic portions of the molecule are preferably positioned at two ends of an elongated molecular structure.
  • phospholipids used herein means any phospholipid capable of forming liposomes unless otherwise indicated, including lecithin (phosphatidyl choline), phosphatidyl serine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidylinositol and sphingomyelin, but not limited to.
  • lecithin phosphatidyl choline
  • phosphatidyl serine phosphatidyl serine
  • phosphatidylethanolamine phosphatidylglycerol
  • phosphatidylinositol phosphatidylinositol
  • phospholipids useful in this invention are lecithin, most preferably, hydrogenated lecithin.
  • Lecithin can be made from egg, soybean and other plants, most preferably, soybean.
  • Lecithin useful in this invention which is synthetic, semisynthetic or natural, includes, but not limited to, soybean lecithin, distearoylphosphatidyldholine, hydrogenated soybean lecithin, egg lecithin, dioleoylphosphatidylcholine, hydrogenated egg lecithin, dielaidoylphosphatidylcholine, dipalmitoylphosphatidylcholine and dimyristoylphosphatidylcholine.
  • phospholipid used in this invention is hydrogenated soybean lecithin.
  • Trie liposomes may be prepared using high pressure homogenizer, sonicator, microfluidizer, extrusion apparatus or French press.
  • the drug delivery system may be fabricated in the form of hydrogel by using conventional materials for preparing hydrogel such as natural/synthetic hydrophilic polymers, cross-linking agents, skin softner, transdermal enhancer, preservatives, surfactant and pH modifier.
  • gelation agents may be used, including carbopol and/or xanthan gum, preferably carbopol 60 and/or xanthan gum.
  • polyethyleneglycol, xanthan gum, carbopol, carbomer and hydroxypropylcellulose are added in the amount of 0.01-20 wt% based the total weight to water to prepare hydrogel and then a bisphosphonate-based drug and a cationic amine compound are introduced in the amount of 0.01-20.00 wt%.
  • a pharmaceutical composition for preventing or treating a bone disease via transdermal route which comprises (a) a pharmaceutically effective amount of a drug delivery system containing (i) a bisphosphonate- based drug and (ii) a cationic amine compound linked to the bisphosphonate-based drug via an ionic bond; and (b) a pharmaceutically acceptable earner.
  • a method for preventing or treating a bone disease via transdermal route which comprises administering to a subject a pharmaceutical comprising (a) a pharmaceutically effective amount of a drug delivery system containing (i) a bisphosphonate-based drug and (ii) a cationic amine compound linked to the bisphosphonate-based drug via an ionic bond; and (b) a pharmaceutically acceptable earner.
  • the present pharmaceutical composition comprises the drug delivery system described above, the common descriptions between them are omitted in order to avoid undue redundancy leading to the complexity of this specification.
  • the drug delivery system is contained in the amount of 0.001-50 wt% (more preferably 0.1-40 wt%, most preferably 10-30 wt ) based on the total weight of the composition.
  • the pharmaceutical composition of this invention is provided in various forms such as solution, lotion, W/O emulsion, O/W emulsion, suspension, liposome, gel, hydrogel, cream, paste, patch or ointment
  • the bone disease prevented or treated by the present pharmaceutical composition includes osteoporosis, Pagers disease, rickets, osteopenia, rheumatoid arthritis, osteomalacia, renal osteodystrophy, osteogenesis imperfecta, hyperthyroidism, bone loss due to rheumatoid arthritis, inflammatory arthritis, subchondral osteosclerosis, subchondral osteocystoma, osteophytosis, athralgia, hyperparathyroidism, sarcoidosis and hypercalcemia, more preferably osteoporosis, Pagers disease, rickets, osteomalacia, renal osteodystrophy, hyperthyroidism and hyperparathyroidism, most preferably osteoporosis.
  • the pharmaceutically acceptable earner may be conventional one for formulation, including carbohydrates (e.g., lactose, amylose, dextrose, sucrose, sorbitol, mannitol, starch, cellulose), gum acacia, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpynOlidone, water, salt solutions, alcohols, gum arabic, syrup, vegetable oils (e.g., com oil, cotton-seed oil, peanut oil, olive oil, coconut oil), polyethylene glycols, methyl cellulose, methylhydroxy benzoate, propylhydroxy benzoate, talc, magnesium stearate and mineral oil, but not limited to.
  • carbohydrates e.g., lactose, amylose, dextrose, sucrose, sorbitol, mannitol, starch, cellulose
  • gum acacia calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinyl
  • compositions of this invention further may contain wetting agent, sweetening agent, emulsifier, buffer, suspending agent, preservatives, flavors, perfumes, lubricant, stabilizer, or mixtures of these substances.
  • wetting agent sweetening agent, emulsifier, buffer, suspending agent, preservatives, flavors, perfumes, lubricant, stabilizer, or mixtures of these substances.
  • the pharmaceutical composition of this invention may be administered via transdermal route.
  • the correct dosage of the pharmaceutical compositions of this invention will be varied according to the particular formulation, the mode of application, age, body weight and sex of the patient, diet, time of administration, condition of the patient, drug combinations, reaction sensitivities and severity of the disease. It is understood that the ordinary skilled physician will readily be able to determine and prescribe a correct dosage of this pharmaceutical compositions.
  • suitable dosage unit for human host is to administer once a day with the composition of 0.001-100 mg/kg(body weight) per day.
  • compositions of this invention can be formulatedwith pharmaceutical acceptable carrier and/or vehicle as described above, finally providing several forms including a unit dosage form.
  • the present invention provides drug delivery systems and pharmaceutical compositions ensuring trandermal administration of conventional bisphosphonate-based drugs by forming ionic bonds between bisphosphonate-based drugs and cationic amine compounds.
  • novel approaches of the present invention is to decrease hydrophilicity and increase hydrophobicity of bisphosphonate-based drugs by forming ionic bonds with cationic amine compounds, contributing to dramatic increase in skin penetration into cell membrane.
  • the present invention completely overcomes shortcomings associated with conventional bisphosphonate drugs for oral administration such as poor bioavailability (as much as 1%) and irritation of gastrointestinal tract
  • the drug delivery systems and pharmaceutical compositions of this invention may be prepared in a relatively convenient fashion with no decrease in therapeutic effects of bisphosphonate drugs.
  • the drug delivery systems and pharmaceutical compositions of this invention may be transdermally applied with much higher patient compliance suffering from bone diseases, particularly osteoporosis.
  • mice Male hairless mice (6-8 weeks old) purchased from Orientalbio, Inc. (Korea) were used in our In vitro experiment within one week of delivery.
  • risedronate and diethylenetriamine (DETA) each dissolved in distilled water were homogeneously mixed at molar ratio of 1:1, 1:2 or 1:4 and kept to stand at room temperature for 1 hr. This facilitates the ionic bonding between anionic risedronate and cationic diethylenetriamine (DETA).
  • L-Arginine, L-Lysine were used also to form an ionic bond with risedronate.
  • the concentration of the risedronate ionic complex was 2 wt% and the solution was adjusted to pH 6.
  • hydrogel containing risedronate ionic compound were prepared in accordance witii formulations presented in Table 1.
  • hydrogel was prepared by dissolving polyethylene glycol (PEG), Xanthan gum, carbopol, carbomer and hydroxypropyl cellulose (HPC) in the water solution according to the formula presented below.
  • PEG polyethylene glycol
  • HPC hydroxypropyl cellulose
  • risedronate was added according to the weight ratio shown below.
  • Risedronate ionic compound in Table 1 had a molar ratio of risedronate: DETA of 1:1.
  • the dorsal skin of 6 week old hairless mouse was excised and used for this experiment Hairless mouse was anesthetized with ether and fixed on the surgical table. Subcutaneous fat layer, tissue and blood vessel was carefully removed from epidermal layer.
  • a C-18 column (5 pm diameter particles size, 150 x 4.6 mm dimensions, Waters) was used for separation.
  • a 93/7 of buffer A/bufferB were used as mobile phase, where buffer A consisted of 0.005M pyrophosphate sodium, 0.005M tetrabutyl ammonium hydroxide at the ratio of 1:1, adjusted to pH 7 using phosphoric acid, and buffer B was HPLC grade acetonitrile.
  • the column was operated at a flow rate of 1 ml/min and eluted samples were detected at the UV absorbance at 262 nm with a UV spectrophotometer. Samples were quantified by calibrating the relative area of the sample peaks from the chromatogram. This result is presented in Rg. 2 and Rg. 3.
  • mice Three 6-week old mice were used for each formulation group. Control group used solely risedronate. In two experiment groups (i) the first group used risedronate and L-arginine ionic compound (molar ratio 1:2) and (ii) the second group used risedronate and DEETA ionic compound (molar ratio 1:1). Reagents were mixed homogenously with 1% xanthan gum solution. This solution was applied onto the same size of mouse skin for 30 min, rinsed and monitored for 72 hrs before measuring the skin irritation by taking pictures. The concentration of risedronate was 2 wt %; Xanthan gum was used to increase the viscosity of the solution. Ovariectomized mouse model
  • mice Following a 1 week of adaptation, 14 week old mice underwent ovariectomy. Four days after surgery, drug treatment was initiated once every 2 days, for four weeks. Sham- operated surgical controls underwent laparotomy to give the same stress level as the ovariectomy performed experimental group. The back hair on mice was removed using animal electrical dipper and a shave. After 4 weeks of treatment mouse femurs were sampled and scanned with micro-CT. The range of drug concentration used for the treatment based on risedronate was 0.2 wt% (lowest) to 2 wt% (highest) that were linked with L-arginine via ionic bond. The molar ratio of risedronate to L-arginine is 1:2.
  • anionic risedronate and cationic DETA or amino acids like L-arginine and L-lysine form an ionic compound that makes risedronate less hydrophilic and becomes more hydrophobic, thereby increasing its solubility in organic solvents.
  • a solvent such as xylene (Rg. la) and propylene carbonate (Rg. lb).
  • Rg. 2a shows in vitro skin penetration experiment of risedronate ionic compound, which were previously separated by HPLC.
  • risedronate ionic compound which were previously separated by HPLC.
  • Example group containing risedronate: L- arginine at molar ratio of 1:1, 1:2 and 1:4 showed a time dependent increase in skin penetration.
  • Control group containing risedronate alone alone showed negligent increase of skin penetration during the observation period.
  • Risedronate: L-arginine at the molar ratio of 1:2 showed greater penetration than those at a ratio of 1:4.
  • Rg. 2b shows in nfrpskin penetration of risedronate linked to L-lysine via ionic bonds.
  • Ovariectomized mouse experiment showed an increase in both cortical and cancellous bone area in risedronate treated experimental groups.
  • Experimental group treated with 0.2 wt% risedronate-Arg ionic complex showed a significant increase in bone density, especially in cancellous bone density as shown in micro CT images of Rgs. 7a and 7b.
  • Total bone mineral content, total mineral density and bone volume fraction showed highest increase in 0.2 wt% risedronate-Arg ionic complex treatment group (Rgs. 8a-8e). This increase was higher man that of the sham-operated surgical group, suggesting that bisphosphonate drugs (e.g. risedronate) linked to cationic amine compounds (e.g. Arg) via ion bonds have significant therapeutic effects on osteoporosis by transdermal administration.
  • bisphosphonate drugs e.g. risedronate
  • cationic amine compounds e.g. Arg

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un système d'administration transdermique de médicaments comprenant (i) un médicament à base de bisphosphonate et (ii) un composé aminé cationique lié au médicament à base de bisphosphonate par une liaison ionique, et une composition pharmaceutique comprenant le système d'administration de médicaments pour la prévention ou le traitement d'une maladie osseuse. Les nouvelles approches de la présente invention sont destinées à abaisser et augmenter l'hydrophilie et l'hydrophobie de médicaments à base de bisphosphonate, respectivement, en formant des liaisons ioniques avec des composés aminés cationiques, ce qui contribue à l'augmentation spectaculaire de la pénétration cutanée dans les membranes cellulaires. La présente invention surmonte complètement les défauts associés aux médicaments à base de bisphosphonate conventionnels pour l'administration par voie orale, tels qu'une faible biodisponibilité (jusqu'à 1 %) et l'irritation du tractus gastro-intestinal.
PCT/KR2010/005890 2010-04-19 2010-08-31 Système d'administration transdermique de médicaments et composition pharmaceutique pour la prévention ou le traitement de maladies osseuses Ceased WO2011132826A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20100035969 2010-04-19
KR10-2010-0035969 2010-04-19

Publications (1)

Publication Number Publication Date
WO2011132826A1 true WO2011132826A1 (fr) 2011-10-27

Family

ID=44834333

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/005890 Ceased WO2011132826A1 (fr) 2010-04-19 2010-08-31 Système d'administration transdermique de médicaments et composition pharmaceutique pour la prévention ou le traitement de maladies osseuses

Country Status (1)

Country Link
WO (1) WO2011132826A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399023B2 (en) 2009-07-31 2013-03-19 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
WO2015027328A1 (fr) * 2013-08-30 2015-03-05 Dalhousie University Compositions et méthodes pour enlever des tatouages
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
US9463158B2 (en) 2009-06-24 2016-10-11 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US10093691B2 (en) 2009-07-31 2018-10-09 Grunenthal Gmbh Crystallization method and bioavailability
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability
WO2020148556A1 (fr) * 2019-01-18 2020-07-23 The University Of Birmingham Système d'administration de médicament
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US12138268B2 (en) 2009-06-24 2024-11-12 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
WO2025112946A1 (fr) * 2023-11-30 2025-06-05 重庆医科大学 Utilisation d'arginine et composition pharmaceutique contenant de l'arginine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0892101A (ja) * 1994-09-21 1996-04-09 Teijin Ltd 局所投与用アレンドロン酸ナトリウム製剤
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
KR20060087568A (ko) * 2003-09-18 2006-08-02 노파르티스 아게 비스포스포네이트를 포함하는 제약 제품
KR20080000647A (ko) * 2005-04-28 2008-01-02 오노 야꾸힝 고교 가부시키가이샤 경피 흡수 제제

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0892101A (ja) * 1994-09-21 1996-04-09 Teijin Ltd 局所投与用アレンドロン酸ナトリウム製剤
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
KR20060087568A (ko) * 2003-09-18 2006-08-02 노파르티스 아게 비스포스포네이트를 포함하는 제약 제품
KR20080000647A (ko) * 2005-04-28 2008-01-02 오노 야꾸힝 고교 가부시키가이샤 경피 흡수 제제

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9675619B2 (en) 2009-06-24 2017-06-13 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US10898489B2 (en) 2009-06-24 2021-01-26 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US12138268B2 (en) 2009-06-24 2024-11-12 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US10172865B2 (en) 2009-06-24 2019-01-08 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US10682357B2 (en) 2009-06-24 2020-06-16 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US9463158B2 (en) 2009-06-24 2016-10-11 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US9492458B2 (en) 2009-06-24 2016-11-15 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US9737543B2 (en) 2009-06-24 2017-08-22 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US9334296B2 (en) 2009-07-31 2016-05-10 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US10323052B2 (en) 2009-07-31 2019-06-18 Grunenthal Gmbh Crystallization method and bioavailability
US10093691B2 (en) 2009-07-31 2018-10-09 Grunenthal Gmbh Crystallization method and bioavailability
US8399023B2 (en) 2009-07-31 2013-03-19 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US8933057B2 (en) 2009-07-31 2015-01-13 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US10519176B2 (en) 2010-11-24 2019-12-31 Thar Pharma, Llc Crystalline forms
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
US9498482B2 (en) 2010-12-29 2016-11-22 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US9833456B2 (en) 2010-12-29 2017-12-05 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US10105302B2 (en) 2013-08-30 2018-10-23 Dalhousie University Compositions and methods for the removal of tattoos
AU2014311225B2 (en) * 2013-08-30 2019-12-19 Dalhousie University Compositions and methods for the removal of tattoos
US11344490B2 (en) 2013-08-30 2022-05-31 Dalhousie University Compositions and methods for the removal of tattoos
US9801799B2 (en) 2013-08-30 2017-10-31 Dalhousia University Compositions and methods for the removal of tattoos
WO2015027328A1 (fr) * 2013-08-30 2015-03-05 Dalhousie University Compositions et méthodes pour enlever des tatouages
US12226508B2 (en) 2013-08-30 2025-02-18 Dalhousie University Compositions and methods for the removal of tattoos
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability
WO2020148556A1 (fr) * 2019-01-18 2020-07-23 The University Of Birmingham Système d'administration de médicament
CN113329735A (zh) * 2019-01-18 2021-08-31 伯明翰大学 药物递送系统
WO2025112946A1 (fr) * 2023-11-30 2025-06-05 重庆医科大学 Utilisation d'arginine et composition pharmaceutique contenant de l'arginine

Similar Documents

Publication Publication Date Title
WO2011132826A1 (fr) Système d'administration transdermique de médicaments et composition pharmaceutique pour la prévention ou le traitement de maladies osseuses
US10323052B2 (en) Crystallization method and bioavailability
CN1272013C (zh) 二膦酸盐在制备用于治疗骨更新异常增加的病症的药物中的应用
RU2238736C2 (ru) Фармацевтическая парентеральная композиция, содержащая бифосфонат
EP3158867B1 (fr) Un procédé pour augmenter la solubilite aqueuse d'un acide bisphosphonique ou d'un bisphosphonate
EP2503992B1 (fr) Formulations de bisphosphonates et de vitamine d se prêtant à une administration intermittente par voie intramusculaire et sous-cutanée
KR20030057544A (ko) 통증 치료를 위한 비스포스포네이트의 용도
NZ270445A (en) Concentrated aqueous solution of argatroban; solution prepared at time of use
WO2016025307A1 (fr) Formes galéniques d'acide zolédronique pour le traitement de la douleur
WO2008116809A1 (fr) Compositions pharmaceutiques contenant un bisphosphonate et de la vitamine d
CN104363894B (zh) 用于治疗关节疼痛或运动性降低的囊泡制剂
JP2002533385A (ja) 感染症の予防及び治療へのビスホスホネートの使用
KR20120064501A (ko) 비스포스포네이트의 경피 투여용 약제학적 조성물
WO2003068241A1 (fr) Preparations percutanees
CA2490022A1 (fr) Plate-forme pour formulations transdermiques
US20050208119A1 (en) Encapsulated oral chelating preparations
US8323687B2 (en) Pharmaceutical composition for the prevention and treatment of bone tissue resorption of various etiology
US20050208118A1 (en) Preparations of encapsulated bioavailable chelating agents for detoxifying humans and animals
US11819507B2 (en) Cholecalciferol sulfate salts and their use for the treatment of vitamin D deficiency
CN110167561A (zh) 用于治疗骨关节炎的组合物
JPH08277223A (ja) 高カルシウム血症治療のための薬剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10850309

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10850309

Country of ref document: EP

Kind code of ref document: A1